Table 3.
Improvements in disease activity over the FUP period in the PsA cohort
| All PsA cohort (n = 596) | Etanercept (n = 333) | Infliximab (n = 171) | Adalimumab (n = 92) | |
|---|---|---|---|---|
| 6-Month follow-up (na = 480) | ||||
| Baseline DAS-28,b mean (s.d.) | 6.2 (1.1) | 6.1 (1.2) | 6.3 (1.1) | 6.0 (1.0) |
| 6-Month DAS-28, mean (s.d.) | 3.5 (1.5) | 3.3 (1.4) | 3.9 (1.6) | 3.32 (1.37) |
| Mean diff. (s.d.) in DAS-28 | 2.6 (1.6) | 2.8 (1.6) | 2.3 (1.7) | 2.66 (1.40) |
| EULAR response | ||||
| Good, n (%) | 180 (38) | 109 (43) | 35 (24) | 36 (43) |
| Moderate, n (%) | 184 (38) | 92 (37) | 55 (38) | 37 (45) |
| None, n (%) | 116 (24) | 51 (20) | 55 (38) | 10 (12) |
| EULAR response in those remaining on initial therapy | ||||
| Good, n (%) | 180 (45) | 109 (40) | 35 (338) | 36 (47) |
| Moderate, n (%) | 184 (46) | 92 (42) | 55 (52) | 37 (48) |
| None, n (%) | 35 (9) | 16 (83) | 15 (14) | 4 (5) |
| 12-Month follow-up (na = 441) | ||||
| 12-Month DAS-28, mean (s.d.) | 3.4 (1.5) | 3.2 (1.4) | 3.7 (1.7) | 3.2 (1.5) |
| Mean diff. (s.d.) in DAS-28 | 2.7 (1.7) | 2.9 (1.6) | 2.4 (1.9) | 2.9 (1.6) |
| EULAR response | ||||
| Good, n (%) | 183 (42) | 112 (48) | 35 (26) | 36 (50) |
| Moderate, n (%) | 127 (29) | 71 (30) | 36 (27) | 20 (28) |
| None, n (%) | 131 (29) | 51 (22) | 64 (47) | 16 (22) |
| EULAR response in those remaining on initial therapy | ||||
| Good, n (%) | 183 (53) | 112 (55) | 35 (43) | 36 (60) |
| Moderate, n (%) | 127 (37) | 71 (35) | 36 (44) | 20 (33) |
| None, n (%) | 34 (10) | 19 (10) | 11 (13) | 4 (7) |
| 18-Month follow-up (na = 384) | ||||
| 18-Month DAS-28, mean (s.d.) | 3.3 (1.5) | 3.3 (1.4) | 3.5 (1.6) | 3.2 (1.5) |
| Mean diff. (s.d.) in DAS-28 | 2.8 (1.7) | 2.9 (1.7) | 2.7 (1.8) | 2.8 (1.7) |
| EULAR response | ||||
| Good, n (%) | 150 (39) | 89 (43) | 35 (29) | 26 (48) |
| Moderate, n (%) | 112 (29) | 71 (34) | 28 (23) | 13 (24) |
| None, n (%) | 122 (32) | 48 (23) | 59 (48) | 15 (28) |
| EULAR response in those remaining on initial therapy | ||||
| Good, n (%) | 150 (53) | 89 (52) | 35 (53) | 26 (58) |
| Moderate, n (%) | 112 (40) | 71 (42) | 28 (42) | 13 (29) |
| None, n (%) | 21 (7) | 12 (7) | 3 (5) | 6 (13) |
aNumber of patients with complete data on DAS-28 at follow-up.
bBaseline DAS-28 score in only those who had data on disease activity at the corresponding follow-up questionnaire.